WallStSmart
CLLS

Cellectis SA

NASDAQ: CLLS · HEALTHCARE · BIOTECHNOLOGY

$3.90
+4.56% today

Updated 2026-04-30

Market cap
$391.30M
P/E ratio
P/S ratio
4.92x
EPS (TTM)
$-0.67
Dividend yield
52W range
$1 – $5
Volume
0.0M

Cellectis SA (CLLS) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+33.0%
Last 4 quarters
Revenue YoY growth
-18.3%
Most recent quarter
EPS YoY growth
-50.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+0.3%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+13.4%
2025-11-07
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-11$-0.24+18.6%$3.82$3.33-12.8%
2025-11-07$0.01+104.3%$3.13$3.55+13.4%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.29$-0.24+18.6%$10.40M-18.3%
2025-09-30$-0.23$0.01+104.3%$35.17M+117.1%
2025-06-30$-0.20$-0.24-20.0%$16.73M+107.5%
2025-03-31$-0.24$-0.17+29.2%$10.65M+135.3%
2024-12-31$-0.09$-0.16-77.8%$12.72M+4393.6%
2024-09-30$-0.21$-0.23-9.5%$16.20M+10351.6%
2024-06-30$-0.30$-0.28+6.7%$8.06M+4428.7%
2024-03-31$-0.22$-0.70-218.2%$4.53M+3157.6%
2023-12-31$-0.22$-0.70-218.2%$283000.00
2023-09-30$-0.42$-0.31+26.2%$155000.00
2023-06-30$-0.45$-0.19+57.8%$178000.00
2023-03-31$-0.48$-0.58-20.8%$139000.00

Frequently asked questions

Has Cellectis SA beaten earnings estimates?
Cellectis SA has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +33.0% over the last 4 quarters.
How does CLLS stock react to earnings?
CLLS stock has moved an average of +0.3% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Cellectis SA's revenue growth rate?
Cellectis SA reported year-over-year revenue growth of -18.3% in its most recent quarter, with EPS growing -50.0% year-over-year.